{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:07:50Z","timestamp":1787317670507,"version":"build-2736575974"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009068","name":"Universit\u00e4t Bern","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009068","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Although consensus guidelines recommend dopamine agonists (DAs) as the first-line approach in prolactinomas, some patients may opt instead for upfront surgery, with the goal of minimizing the need for continuation of DAs over the long term. While this approach can be recommended in selected patients with a microprolactinoma, the indication for upfront surgery in macroprolactinomas remains controversial, with limited long-term data in large cohorts. We aimed at elucidating whether first-line surgery is equally safe and effective for patients with micro- or macroprolactinomas not extending beyond the median carotid line (i.e., Knosp grade\u2009\u2264\u20091).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>Retrospective study of patients with prolactinomas Knosp grade\u2009\u2264\u20091 treated with upfront surgery. The primary endpoint was patients\u2019 dependence on DAs at last follow-up. The secondary endpoint was postoperative complications. Independent risk factors for long-term dependence on DAs were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A microadenoma was noted in 45 patients (52%) and a macroadenoma in 41 (48%), with 17 (20%) harboring a Knosp grade 1 prolactinoma. Median follow-up was 80\u00a0months. First-line surgery resulted in long-term remission in 31 patients (72%) with a microprolactinoma and in 18 patients (45%) with a macroprolactinoma (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02). DA therapy was ultimately required in 11 patients (24%) with microadenomas vs. 20 (49%) with macroadenomas (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03). As for the latter, DA was required in 13 patients (76%) with Knosp grade 1 macroadenomas vs. 7 patients (29%) with Knosp grade 0 macroadenomas (p\u2009=\u20090.004). There was no mortality, and morbidity was minimal. Knosp grade 1 prolactinomas (OR 7.3, 95% CI 1.4\u201337.7,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02) but not adenoma size (i.e., macroprolactinomas) were an independent predictor of long-term dependence on DAs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>First-line surgery in patients with microprolactinomas or macroprolactinomas Knosp grade 0 resulted in a good chance of non-dependency on DA therapy. However, in patients with prolactinomas Knosp grade 1, first-line surgery cannot be recommended, as adjuvant DA therapy after surgery is required in the majority of them over the long term.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40618-021-01569-6","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T02:02:56Z","timestamp":1618279376000},"page":"2621-2633","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1764-688X","authenticated-orcid":false,"given":"L.","family":"Andereggen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. H.","family":"Andres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. M.","family":"Luedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"El-Koussy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. R.","family":"Widmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. W.","family":"Seiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Christ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,13]]},"reference":[{"key":"1569_CR1","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/j.1365-2265.2007.02905.x","volume":"67","author":"A Colao","year":"2007","unstructured":"Colao A, Di Sarno A, Guerra E et al (2007) Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol 67:426\u2013433. https:\/\/doi.org\/10.1111\/j.1365-2265.2007.02905.x","journal-title":"Clin Endocrinol"},{"key":"1569_CR2","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1210\/jc.2009-0177","volume":"94","author":"M Kars","year":"2009","unstructured":"Kars M, Souverein PC, Herings RM et al (2009) Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab 94:2729\u20132734. https:\/\/doi.org\/10.1210\/jc.2009-0177","journal-title":"J Clin Endocrinol Metab"},{"key":"1569_CR3","doi-asserted-by":"publisher","unstructured":"Levy A. Pituitary disease: presentation, diagnosis, and management. J Neurol Neurosurg Psychiatry 2004; 75 Suppl 3: iii47\u201352 DOI: https:\/\/doi.org\/10.1136\/jnnp.2004.045740","DOI":"10.1136\/jnnp.2004.045740"},{"key":"1569_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jocn.2017.01.028","volume":"40","author":"L Andereggen","year":"2017","unstructured":"Andereggen L, Mono ML, Kellner-Weldon F et al (2017) Cluster headache and macroprolactinoma: case report of a rare, but potential important causality. J Clin Neurosci 40:62\u201364. https:\/\/doi.org\/10.1016\/j.jocn.2017.01.028","journal-title":"J Clin Neurosci"},{"key":"1569_CR5","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1530\/EJE-11-1000","volume":"166","author":"V Primeau","year":"2012","unstructured":"Primeau V, Raftopoulos C, Maiter D (2012) Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Euro J Endocrinol \/ Euro Federation Endocrine Soc 166:779\u2013786. https:\/\/doi.org\/10.1530\/EJE-11-1000","journal-title":"Euro J Endocrinol \/ Euro Federation Endocrine Soc"},{"key":"1569_CR6","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3171\/2010.11.JNS101369","volume":"114","author":"MC Oh","year":"2011","unstructured":"Oh MC, Aghi MK (2011) Dopamine agonist-resistant prolactinomas. J Neurosurg 114:1369\u20131379. https:\/\/doi.org\/10.3171\/2010.11.JNS101369","journal-title":"J Neurosurg"},{"key":"1569_CR7","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3389\/fendo.2018.00636","volume":"9","author":"Q Ma","year":"2018","unstructured":"Ma Q, Su J, Li Y et al (2018) The chance of permanent cure for micro- and macroprolactinomas, medication or surgery? A systematic review and meta-analysis. Front Endocrinol (Lausanne) 9:636. https:\/\/doi.org\/10.3389\/fendo.2018.00636","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1569_CR8","doi-asserted-by":"publisher","unstructured":"Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F et al. Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis. The Journal of clinical endocrinology and metabolism 2019: DOI: https:\/\/doi.org\/10.1210\/clinem\/dgz144","DOI":"10.1210\/clinem\/dgz144"},{"key":"1569_CR9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s11102-016-0766-6","volume":"20","author":"T Ogiwara","year":"2017","unstructured":"Ogiwara T, Horiuchi T, Nagm A et al (2017) Significance of surgical management for cystic prolactinoma. Pituitary 20:225\u2013230. https:\/\/doi.org\/10.1007\/s11102-016-0766-6","journal-title":"Pituitary"},{"key":"1569_CR10","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.nec.2019.05.010","volume":"30","author":"DA Donoho","year":"2019","unstructured":"Donoho DA, Laws ER Jr (2019) The role of surgery in the management of prolactinomas. Neurosurg Clin N Am 30:509\u2013514. https:\/\/doi.org\/10.1016\/j.nec.2019.05.010","journal-title":"Neurosurg Clin N Am"},{"key":"1569_CR11","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3275\/760410.1007\/BF03347092","volume":"34","author":"V Vasilev","year":"2011","unstructured":"Vasilev V, Daly AF, Vroonen L et al (2011) Resistant prolactinomas. J Endocrinol Invest 34:312\u2013316. https:\/\/doi.org\/10.3275\/760410.1007\/BF03347092","journal-title":"J Endocrinol Invest"},{"key":"1569_CR12","doi-asserted-by":"publisher","first-page":"e5833","DOI":"10.1097\/MD.0000000000005833","volume":"96","author":"YJ Song","year":"2017","unstructured":"Song YJ, Chen MT, Lian W et al (2017) Surgical treatment for male prolactinoma: a retrospective study of 184 cases. Medicine (Baltimore) 96:e5833. https:\/\/doi.org\/10.1097\/MD.0000000000005833","journal-title":"Medicine (Baltimore)"},{"key":"1569_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","volume":"65","author":"FF Casanueva","year":"2006","unstructured":"Casanueva FF, Molitch ME, Schlechte JA et al (2006) Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol 65:265\u2013273. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02562.x","journal-title":"Clin Endocrinol"},{"key":"1569_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1210\/jc.2009-1238","volume":"95","author":"OM Dekkers","year":"2010","unstructured":"Dekkers OM, Lagro J, Burman P et al (2010) Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 95:43\u201351. https:\/\/doi.org\/10.1210\/jc.2009-1238","journal-title":"J Clin Endocrinol Metab"},{"key":"1569_CR15","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","volume":"84","author":"J Verhelst","year":"1999","unstructured":"Verhelst J, Abs R, Maiter D et al (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84:2518\u20132522. https:\/\/doi.org\/10.1210\/jcem.84.7.5810","journal-title":"J Clin Endocrinol Metab"},{"key":"1569_CR16","doi-asserted-by":"publisher","unstructured":"Webster J, Piscitelli G, Polli A et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. The New England journal of medicine 1994; 331: 904\u2013909 DOI: https:\/\/doi.org\/10.1056\/NEJM199410063311403","DOI":"10.1056\/NEJM199410063311403"},{"key":"1569_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1365-2265.2008.03458.x","volume":"70","author":"N Herring","year":"2009","unstructured":"Herring N, Szmigielski C, Becher H et al (2009) Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol 70:104\u2013108. https:\/\/doi.org\/10.1111\/j.1365-2265.2008.03458.x","journal-title":"Clin Endocrinol"},{"key":"1569_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMoa054830","volume":"356","author":"R Zanettini","year":"2007","unstructured":"Zanettini R, Antonini A, Gatto G et al (2007) Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease. N Engl J Med 356:39\u201346. https:\/\/doi.org\/10.1056\/NEJMoa054830","journal-title":"N Engl J Med"},{"key":"1569_CR19","doi-asserted-by":"publisher","unstructured":"Stiles CE, Tetteh-Wayoe ET, Bestwick J et al. A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with Cabergoline. The Journal of clinical endocrinology and metabolism 2018: DOI: https:\/\/doi.org\/10.1210\/jc.2018-01071","DOI":"10.1210\/jc.2018-01071"},{"key":"1569_CR20","doi-asserted-by":"publisher","first-page":"e711","DOI":"10.1210\/clinem\/dgaa882","volume":"106","author":"CE Stiles","year":"2021","unstructured":"Stiles CE, Lloyd G, Bhattacharyya S et al (2021) Incidence of cabergoline-associated valvulopathy in primary care patients with prolactinoma using hard cardiac endpoints. J Clin Endocrinol Metab 106:e711\u2013e720. https:\/\/doi.org\/10.1210\/clinem\/dgaa882","journal-title":"J Clin Endocrinol Metab"},{"key":"1569_CR21","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1001\/jamainternmed.2014.5262","volume":"174","author":"TJ Moore","year":"2014","unstructured":"Moore TJ, Glenmullen J, Mattison DR (2014) Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med 174:1930\u20131933. https:\/\/doi.org\/10.1001\/jamainternmed.2014.5262","journal-title":"JAMA Intern Med"},{"key":"1569_CR22","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1001\/jamainternmed.2014.4097","volume":"174","author":"HD Weiss","year":"2014","unstructured":"Weiss HD, Pontone GM (2014) Dopamine receptor agonist drugs and impulse control disorders. JAMA Intern Med 174:1935\u20131937. https:\/\/doi.org\/10.1001\/jamainternmed.2014.4097","journal-title":"JAMA Intern Med"},{"key":"1569_CR23","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/cen.12375","volume":"80","author":"I Bancos","year":"2014","unstructured":"Bancos I, Nannenga MR, Bostwick JM et al (2014) Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clin Endocrinol 80:863\u2013868. https:\/\/doi.org\/10.1111\/cen.12375","journal-title":"Clin Endocrinol"},{"key":"1569_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1530\/EJE-18-0682","volume":"180","author":"AG Ioachimescu","year":"2019","unstructured":"Ioachimescu AG, Fleseriu M, Hoffman AR et al (2019) Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. Euro J Endocrinol \/ Euro Federation Endocrine Soc 180:31\u201340. https:\/\/doi.org\/10.1530\/EJE-18-0682","journal-title":"Euro J Endocrinol \/ Euro Federation Endocrine Soc"},{"key":"1569_CR25","doi-asserted-by":"publisher","unstructured":"Andereggen L, Frey J, Christ E. Long-term IGF-1 monitoring in prolactinoma patients treated with cabergoline might not be indicated. Endocrine 2020: DOI: https:\/\/doi.org\/10.1007\/s12020-020-02557-1","DOI":"10.1007\/s12020-020-02557-1"},{"key":"1569_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ando.2020.12.008","volume":"82","author":"F Castinetti","year":"2021","unstructured":"Castinetti F, Albarel F, Amodru V et al (2021) The risks of medical treatment of prolactinoma. Ann Endocrinol 82:15\u201319. https:\/\/doi.org\/10.1016\/j.ando.2020.12.008","journal-title":"Ann Endocrinol"},{"key":"1569_CR27","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1530\/EJE-16-0087","volume":"175","author":"M Tampourlou","year":"2016","unstructured":"Tampourlou M, Trifanescu R, Paluzzi A et al (2016) THERAPY OF ENDOCRINE DISEASE: Surgery in microprolactinomas: effectiveness and risks based on contemporary literature. Euro J Endocrinol \/ Euro Federation Endocrine Soc 175:R89-96. https:\/\/doi.org\/10.1530\/EJE-16-0087","journal-title":"Euro J Endocrinol \/ Euro Federation Endocrine Soc"},{"key":"1569_CR28","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s11102-010-0283-y","volume":"14","author":"M Babey","year":"2011","unstructured":"Babey M, Sahli R, Vajtai I et al (2011) Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists. Pituitary 14:222\u2013230. https:\/\/doi.org\/10.1007\/s11102-010-0283-y","journal-title":"Pituitary"},{"key":"1569_CR29","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/neuros\/nyy385","volume":"85","author":"A Micko","year":"2019","unstructured":"Micko A, Vila G, Hoftberger R et al (2019) Endoscopic transsphenoidal surgery of microprolactinomas: a reappraisal of cure rate based on radiological criteria. Neurosurgery 85:508\u2013515. https:\/\/doi.org\/10.1093\/neuros\/nyy385","journal-title":"Neurosurgery"},{"key":"1569_CR30","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.wneu.2016.10.059","volume":"97","author":"L Andereggen","year":"2017","unstructured":"Andereggen L, Frey J, Andres RH et al (2017) Long-term follow-up of primary medical versus surgical treatment of prolactinomas in men: effects on hyperprolactinemia, hypogonadism, and bone health. World Neurosurg 97:595\u2013602. https:\/\/doi.org\/10.1016\/j.wneu.2016.10.059","journal-title":"World Neurosurg"},{"key":"1569_CR31","doi-asserted-by":"publisher","unstructured":"Andereggen L, Frey J, Andres RH et al. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas. Endocrine 2017; 55: 223\u2013230 DOI: https:\/\/doi.org\/10.1007\/s12020-016-1115-2","DOI":"10.1007\/s12020-016-1115-2"},{"key":"1569_CR32","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.ando.2016.07.004","volume":"77","author":"L Kepenekian","year":"2016","unstructured":"Kepenekian L, Cebula H, Castinetti F et al (2016) Long-term outcome of macroprolactinomas. Ann Endocrinol 77:641\u2013648. https:\/\/doi.org\/10.1016\/j.ando.2016.07.004","journal-title":"Ann Endocrinol"},{"key":"1569_CR33","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/cen.12418","volume":"81","author":"AI Green","year":"2014","unstructured":"Green AI, Sherlock M, Stewart PM et al (2014) Extensive experience in the management of macroprolactinomas. Clin Endocrinol 81:85\u201392. https:\/\/doi.org\/10.1111\/cen.12418","journal-title":"Clin Endocrinol"},{"key":"1569_CR34","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1038\/s41598-021-84606-x","volume":"11","author":"L Andereggen","year":"2021","unstructured":"Andereggen L, Frey J, Andres RH et al (2021) Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas. Sci Rep 11:5122. https:\/\/doi.org\/10.1038\/s41598-021-84606-x","journal-title":"Sci Rep"},{"key":"1569_CR35","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1365-2265.2006.02627.x","volume":"65","author":"N Karavitaki","year":"2006","unstructured":"Karavitaki N, Thanabalasingham G, Shore HC et al (2006) Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol 65:524\u2013529. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02627.x","journal-title":"Clin Endocrinol"},{"key":"1569_CR36","doi-asserted-by":"crossref","unstructured":"Cattaneo F, Kappeler D, Muller B. Macroprolactinaemia, the major unknown in the differential diagnosis of hyperprolactinaemia. Swiss medical weekly 2001; 131: 122-126 DOI: 2001\/09\/smw-06127","DOI":"10.4414\/smw.2001.06127"},{"key":"1569_CR37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR et al (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:273\u2013288. https:\/\/doi.org\/10.1210\/jc.2010-1692","journal-title":"J Clin Endocrinol Metab"},{"key":"1569_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.neurad.2019.05.004","volume":"48","author":"L Andereggen","year":"2021","unstructured":"Andereggen L, Gralla J, Schroth G et al (2021) Influence of inferior petrosal sinus drainage symmetry on detection of adenomas in Cushing\u2019s syndrome. J Neuroradiol 48:10\u201315. https:\/\/doi.org\/10.1016\/j.neurad.2019.05.004","journal-title":"J Neuroradiol"},{"key":"1569_CR39","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00234-011-0915-6","volume":"54","author":"L Andereggen","year":"2012","unstructured":"Andereggen L, Schroth G, Gralla J et al (2012) Selective inferior petrosal sinus sampling without venous outflow diversion in the detection of a pituitary adenoma in Cushing\u2019s syndrome. Neuroradiology 54:495\u2013503. https:\/\/doi.org\/10.1007\/s00234-011-0915-6","journal-title":"Neuroradiology"},{"key":"1569_CR40","doi-asserted-by":"publisher","unstructured":"Knosp E, Steiner E, Kitz K et al. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993; 33: 610\u2013617; discussion 617\u2013618 DOI: https:\/\/doi.org\/10.1227\/00006123-199310000-00008","DOI":"10.1227\/00006123-199310000-00008"},{"key":"1569_CR41","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3171\/2014.12.JNS141083","volume":"122","author":"AS Micko","year":"2015","unstructured":"Micko AS, Wohrer A, Wolfsberger S et al (2015) Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J Neurosurg 122:803\u2013811. https:\/\/doi.org\/10.3171\/2014.12.JNS141083","journal-title":"J Neurosurg"},{"key":"1569_CR42","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00401-017-1769-8","volume":"134","author":"MBS Lopes","year":"2017","unstructured":"Lopes MBS (2017) The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 134:521\u2013535. https:\/\/doi.org\/10.1007\/s00401-017-1769-8","journal-title":"Acta Neuropathol"},{"key":"1569_CR43","doi-asserted-by":"publisher","first-page":"697065","DOI":"10.1155\/2015\/697065","volume":"2015","author":"I Kruljac","year":"2015","unstructured":"Kruljac I, Kirigin LS, Strinovic M et al (2015) Treatment of prolactinomas in low-income countries. Int J Endocrinol 2015:697065. https:\/\/doi.org\/10.1155\/2015\/697065","journal-title":"Int J Endocrinol"},{"key":"1569_CR44","doi-asserted-by":"publisher","first-page":"762","DOI":"10.3171\/jns.2000.93.5.0762","volume":"93","author":"RW Seiler","year":"2000","unstructured":"Seiler RW, Mariani L (2000) Sellar reconstruction with resorbable vicryl patches, gelatin foam, and fibrin glue in transsphenoidal surgery: a 10-year experience with 376 patients. J Neurosurg 93:762\u2013765. https:\/\/doi.org\/10.3171\/jns.2000.93.5.0762","journal-title":"J Neurosurg"},{"key":"1569_CR45","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40618-014-0212-4","volume":"38","author":"A Arduc","year":"2015","unstructured":"Arduc A, Gokay F, Isik S et al (2015) Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience. J Endocrinol Invest 38:447\u2013453. https:\/\/doi.org\/10.1007\/s40618-014-0212-4","journal-title":"J Endocrinol Invest"},{"key":"1569_CR46","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/ncpendmet0162","volume":"2","author":"JA Wass","year":"2006","unstructured":"Wass JA (2006) When to discontinue treatment of prolactinoma? Nat Clin Pract Endocrinol Metab 2:298\u2013299. https:\/\/doi.org\/10.1038\/ncpendmet0162","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"1569_CR47","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1056\/NEJMoa022657","volume":"349","author":"A Colao","year":"2003","unstructured":"Colao A, Di Sarno A, Cappabianca P et al (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349:2023\u20132033. https:\/\/doi.org\/10.1056\/NEJMoa022657","journal-title":"N Engl J Med"},{"key":"1569_CR48","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1530\/EJE-16-0897","volume":"176","author":"J Eroukhmanoff","year":"2017","unstructured":"Eroukhmanoff J, Tejedor I, Potorac I et al (2017) MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment. Euro J Endocrinol \/ Euro Federation Endocrine Soc 176:323\u2013328. https:\/\/doi.org\/10.1530\/EJE-16-0897","journal-title":"Euro J Endocrinol \/ Euro Federation Endocrine Soc"},{"key":"1569_CR49","doi-asserted-by":"publisher","unstructured":"Varlamov EV, Hinojosa-Amaya JM, Fleseriu M. Magnetic resonance imaging inthe management of prolactinomas; a review of the evidence. Pituitary 2019: DOI: https:\/\/doi.org\/10.1007\/s11102-019-01001-6","DOI":"10.1007\/s11102-019-01001-6"},{"key":"1569_CR50","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jama.2016.19699","volume":"317","author":"ME Molitch","year":"2017","unstructured":"Molitch ME (2017) Diagnosis and treatment of pituitary adenomas: a review. JAMA 317:516\u2013524. https:\/\/doi.org\/10.1001\/jama.2016.19699","journal-title":"JAMA"},{"key":"1569_CR51","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1136\/jnnp-2013-306043","volume":"85","author":"B Demartini","year":"2014","unstructured":"Demartini B, Ricciardi L, Ward A et al (2014) Dopamine agonist withdrawal syndrome (DAWS) in a patient with a microprolactinoma. J Neurol Neurosurg Psychiatry 85:471. https:\/\/doi.org\/10.1136\/jnnp-2013-306043","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1569_CR52","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11102-019-01016-z","volume":"23","author":"J Honegger","year":"2020","unstructured":"Honegger J, Nasi-Kordhishti I, Aboutaha N et al (2020) Surgery for prolactinomas: a better choice? Pituitary 23:45\u201351. https:\/\/doi.org\/10.1007\/s11102-019-01016-z","journal-title":"Pituitary"},{"key":"1569_CR53","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/s0140-6736(82)92756-8","volume":"2","author":"AM Landolt","year":"1982","unstructured":"Landolt AM, Keller PJ, Froesch ER et al (1982) Bromocriptine: Does it jeopardise the result of later surgery for prolactinomas? Lancet 2:657\u2013658. https:\/\/doi.org\/10.1016\/s0140-6736(82)92756-8","journal-title":"Lancet"},{"key":"1569_CR54","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11102-010-0261-4","volume":"14","author":"M Menucci","year":"2011","unstructured":"Menucci M, Quinones-Hinojosa A, Burger P et al (2011) Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary 14:68\u201374. https:\/\/doi.org\/10.1007\/s11102-010-0261-4","journal-title":"Pituitary"},{"key":"1569_CR55","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4158\/EP161446.OR","volume":"23","author":"D Donegan","year":"2017","unstructured":"Donegan D, Atkinson JL, Jentoft M et al (2017) Surgical outcomes of prolactinomas in recent era: results of a heterogenous group. Endocr Pract 23:37\u201345. https:\/\/doi.org\/10.4158\/EP161446.OR","journal-title":"Endocr Pract"},{"key":"1569_CR56","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1210\/jcem-58-6-1179","volume":"58","author":"AM Landolt","year":"1984","unstructured":"Landolt AM, Osterwalder V (1984) Perivascular fibrosis in prolactinomas: is it increased by bromocriptine? J Clin Endocrinol Metab 58:1179\u20131183. https:\/\/doi.org\/10.1210\/jcem-58-6-1179","journal-title":"J Clin Endocrinol Metab"},{"key":"1569_CR57","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrn3475","volume":"14","author":"KS Button","year":"2013","unstructured":"Button KS, Ioannidis JP, Mokrysz C et al (2013) Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci 14:365\u2013376. https:\/\/doi.org\/10.1038\/nrn3475","journal-title":"Nat Rev Neurosci"},{"key":"1569_CR58","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s11102-018-0913-3","volume":"21","author":"DJ Lobatto","year":"2018","unstructured":"Lobatto DJ, Steffens ANV, Zamanipoor Najafabadi AH et al (2018) Work disability and its determinants in patients with pituitary tumor-related disease. Pituitary 21:593\u2013604. https:\/\/doi.org\/10.1007\/s11102-018-0913-3","journal-title":"Pituitary"},{"key":"1569_CR59","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.wneu.2017.08.087","volume":"108","author":"E Uvelius","year":"2017","unstructured":"Uvelius E, Castelo N, Kahlon B et al (2017) Quality of life and work capacity are unrelated to approach or complications after pituitary surgery. World neurosurgery 108:24\u201332. https:\/\/doi.org\/10.1016\/j.wneu.2017.08.087","journal-title":"World neurosurgery"},{"key":"1569_CR60","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/cen.13915","volume":"90","author":"A Vega-Beyhart","year":"2019","unstructured":"Vega-Beyhart A, Enriquez-Estrada VM, Bello-Chavolla OY et al (2019) Quality of life is significantly impaired in both secretory and non-functioning pituitary adenomas. Clin Endocrinol (Oxf) 90:457\u2013467. https:\/\/doi.org\/10.1111\/cen.13915","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1569_CR61","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11102-020-01089-1","volume":"24","author":"M van der Meulen","year":"2021","unstructured":"van der Meulen M, Zamanipoor Najafabadi AH, Lobatto DJ et al (2021) Healthcare utilization and costs among prolactinoma patients: a cross-sectional study and analysis of determinants. Pituitary 24:79\u201395. https:\/\/doi.org\/10.1007\/s11102-020-01089-1","journal-title":"Pituitary"},{"key":"1569_CR62","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.wneu.2015.10.090","volume":"87","author":"PR Jethwa","year":"2016","unstructured":"Jethwa PR, Patel TD, Hajart AF et al (2016) Cost-effectiveness analysis of microscopic and endoscopic transsphenoidal surgery versus medical therapy in the management of microprolactinoma in the United States. World neurosurgery 87:65\u201376. https:\/\/doi.org\/10.1016\/j.wneu.2015.10.090","journal-title":"World neurosurgery"},{"key":"1569_CR63","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3171\/2007.12.17635","volume":"111","author":"A Tabaee","year":"2009","unstructured":"Tabaee A, Anand VK, Barron Y et al (2009) Endoscopic pituitary surgery: a systematic review and meta-analysis. J Neurosurg 111:545\u2013554. https:\/\/doi.org\/10.3171\/2007.12.17635","journal-title":"J Neurosurg"},{"issue":"Suppl 1","key":"1569_CR64","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1530\/eje.1.02352","volume":"156","author":"MC Zatelli","year":"2007","unstructured":"Zatelli MC, Ambrosio MR, Bondanelli M et al (2007) Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds. Euro J Endocrinol \/ Euro Federation Endocrine Soc 156(Suppl 1):S29\u2013S35. https:\/\/doi.org\/10.1530\/eje.1.02352","journal-title":"Euro J Endocrinol \/ Euro Federation Endocrine Soc"},{"key":"1569_CR65","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1530\/EJE-09-0989","volume":"162","author":"M Lafeber","year":"2010","unstructured":"Lafeber M, Stades AM, Valk GD et al (2010) Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Euro J Endocrinol \/ Euro Federation Endocrine Soc 162:667\u2013675. https:\/\/doi.org\/10.1530\/EJE-09-0989","journal-title":"Euro J Endocrinol \/ Euro Federation Endocrine Soc"},{"key":"1569_CR66","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1210\/jc.2013-2254","volume":"99","author":"WM Drake","year":"2014","unstructured":"Drake WM, Stiles CE, Howlett TA et al (2014) A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. J Clin Endocrinol Metab 99:90\u201396. https:\/\/doi.org\/10.1210\/jc.2013-2254","journal-title":"J Clin Endocrinol Metab"},{"key":"1569_CR67","doi-asserted-by":"publisher","first-page":"e13198","DOI":"10.1097\/MD.0000000000013198","volume":"97","author":"YL Han","year":"2018","unstructured":"Han YL, Chen DM, Zhang C et al (2018) Retrospective analysis of 52 patients with prolactinomas following endoscopic endonasal transsphenoidal surgery. Medicine (Baltimore) 97:e13198. https:\/\/doi.org\/10.1097\/MD.0000000000013198","journal-title":"Medicine (Baltimore)"},{"key":"1569_CR68","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1210\/jc.2007-2758","volume":"93","author":"M Ono","year":"2008","unstructured":"Ono M, Miki N, Kawamata T et al (2008) Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 93:4721\u20134727. https:\/\/doi.org\/10.1210\/jc.2007-2758","journal-title":"J Clin Endocrinol Metab"},{"key":"1569_CR69","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1210\/jc.2007-0836","volume":"92","author":"JA Schlechte","year":"2007","unstructured":"Schlechte JA (2007) Long-term management of prolactinomas. J Clin Endocrinol Metab 92:2861\u20132865. https:\/\/doi.org\/10.1210\/jc.2007-0836","journal-title":"J Clin Endocrinol Metab"},{"key":"1569_CR70","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s12020-018-1638-9","volume":"61","author":"E Sosa-Eroza","year":"2018","unstructured":"Sosa-Eroza E, Espinosa E, Ramirez-Renteria C et al (2018) Treatment of multiresistant prolactinomas with a combination of cabergoline and octreotide LAR. Endocrine 61:343\u2013348. https:\/\/doi.org\/10.1007\/s12020-018-1638-9","journal-title":"Endocrine"},{"key":"1569_CR71","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s11102-013-0525-x","volume":"17","author":"R Kwancharoen","year":"2014","unstructured":"Kwancharoen R, Auriemma RS, Yenokyan G et al (2014) Second attempt to withdraw cabergoline in prolactinomas: a pilot study. Pituitary 17:451\u2013456. https:\/\/doi.org\/10.1007\/s11102-013-0525-x","journal-title":"Pituitary"},{"key":"1569_CR72","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s12020-017-1444-9","volume":"59","author":"MY Xia","year":"2018","unstructured":"Xia MY, Lou XH, Lin SJ et al (2018) Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine 59:50\u201361. https:\/\/doi.org\/10.1007\/s12020-017-1444-9","journal-title":"Endocrine"},{"key":"1569_CR73","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s40618-016-0483-z","volume":"39","author":"E Sala","year":"2016","unstructured":"Sala E, Bellaviti Buttoni P, Malchiodi E et al (2016) Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas. J Endocrinol Invest 39:1377\u20131382. https:\/\/doi.org\/10.1007\/s40618-016-0483-z","journal-title":"J Endocrinol Invest"},{"key":"1569_CR74","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11060-019-03325-6","volume":"145","author":"A Bunevicius","year":"2019","unstructured":"Bunevicius A, Laws ER, Vance ML et al (2019) Surgical and radiosurgical treatment strategies for Cushing\u2019s disease. J Neurooncol 145:403\u2013413. https:\/\/doi.org\/10.1007\/s11060-019-03325-6","journal-title":"J Neurooncol"},{"key":"1569_CR75","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s11102-018-0904-4","volume":"21","author":"J Honegger","year":"2018","unstructured":"Honegger J, Grimm F (2018) The experience with transsphenoidal surgery and its importance to outcomes. Pituitary 21:545\u2013555. https:\/\/doi.org\/10.1007\/s11102-018-0904-4","journal-title":"Pituitary"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01569-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-021-01569-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01569-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T23:15:28Z","timestamp":1671837328000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-021-01569-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,13]]},"references-count":75,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1569"],"URL":"https:\/\/doi.org\/10.1007\/s40618-021-01569-6","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,13]]},"assertion":[{"value":"5 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This work has not been previously published and is not under consideration for publication anywhere else. The authors report no conflicts of interest concerning the materials or methods used in this study or the findings specified in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The Human Research Ethics Committee of Bern (Kantonale Ethikkommission KEK Bern, Bern, Switzerland) approved the study (KEK n\u00b0 10\u201310-2006 and 8\u201311-2006)\u00a0and informed consent was obtained. The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors agree to share data upon request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing statement"}}]}}